Colombia’s INVIMA approves Sinotherapeutics’ generic posaconazole delayed-release tablets
November 13, 2026
Source: drugdu
25
On the evening of November 12, Sinotherapeutics (688247) said Colombia’s National Food and Drug Surveillance Institute (INVIMA) had approved its generic application for posaconazole delayed-release tablets. Posaconazole is a triazole antifungal that inhibits ergosterol synthesis and is used for invasive Aspergillus or Candida infections.
The filing said the product had previously received first-generic approvals in the US and China, as well as approvals in Australia, Singapore, Saudi Arabia, Israel, Canada and several EU countries. It also received a special import permit in Vietnam. The Colombian approval allows the company to sell the product there. Sales will depend on local regulation, market conditions and distribution development.
Source: http://finance.eastmoney.com/a/202611123929744731.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- GSK’s application for marketing approval in China for its recombinant herpes zoster vaccine pre-filled syringe formulation has been accepted. November 13, 2026
- Novo Nordisk has submitted an application for marketing approval in China for its once-weekly subcutaneous injection of CagriSema, for long-term weight management. November 13, 2026
- Sansure Biotech receives China registration for a liver cancer diagnostic kit November 13, 2026
- Baheal renames itself as it expands into drug development and manufacturing November 13, 2026
- Everest Medicines receives China approval for 100 mg eravacycline injection November 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
